Genfit announced that it will discontinue the Phase 3 NASH study and concentrate on the developmento of PBC therapeutics.

Genfit (France) announced on July 22, 2020, that it will discontinue Elafibranor's Phase 3 NASH clinical trial and concentrate on developing PBC therapeutics.


RESOLVE-IT Phase 3 clinical trial did not show any improvement in the primary endpoint, resulting in a change in corporate strategy.

Following the recent news of OCA, the drop of Elafibranor, a leading candidate for NASH drug, may influence the development strategy of NASH drugs in the future.